Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3): A 56-week, Open-label, Randomized Clinical Trial
In people with T2DM, male sex, higher BMI, larger waist circumference, and increased plasma triglyceride levels are the main risk factors for hepatic steatosis (MASLD) (Mantovani et al., 2026[48])
No Clinical Proof Despite its promises, BuildLeaf Tirzepatide GLP-1 Herbal Oral Liquid Drops does not list any scientific studies , peer-reviewed papers, or real clinical trials to support its safety or efficacy
Researchers have reported that MOTS-c treatment prevented the development of heart failure in a mouse model, an effect attributed to AMPK activation in the heart muscle and improvements in mitochondrial function